About this trial
The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening.
Eligibility criteria
Qualifiers
Confirmed diagnosis of breast cancer
Ability to obtain physical positioning for perometry (e.g. abducting shoulder to 90 degrees) and BIS measurements (e.g. standing without aid)
Disqualifiers
Evidence of distant metastatic disease that may cause edema,
Previous breast cancer
History of lymphedema
Pregnancy at the time of accrual and/or cardiac implants (contraindications for BIS)
Trial design
Treatments tested in this trial
- Breast Cancer-Related Lymphedema Screening
Treatment groups
Sponsors and collaborators
Massachusetts General Hospital
Lead sponsor
National Cancer Institute (NCI)
Collaborator